ClinicalTrials.gg
CompletedNCT03873415Updated Nov 26, 2019

Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males

A Phase 1 interventional study of BMS-986165 in Psoriasis, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-26.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2019, 7 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing deucravacitinib in Psoriasis — 6 open to participants now, 6 under way, 4 of them phase 3. deucravacitinib · Psoriasis.

Enrollment
21st of 26
9 · median 102
Started
2019
with 3 others
Phase 1
6 of 26
none open now
Registered
8th of 26
by date
Lead sponsor
18 of 26
Bristol-Myers Squibb

Among the 26 studies testing deucravacitinib in Psoriasis, this one is the 21st largest by enrollment, is one of 4 that started in 2019, is one of 6 in phase 1, and was the 8th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 26 studies testing deucravacitinib in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About deucravacitinib

deucravacitinib: first FDA approval 2022 (SOTYKTU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing deucravacitinib in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate sites of gut absorption of BMS-986165 in males

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • of 18.0 to 32.0 kg/m2, inclusive, and weight ≥ 50 kg, at screening
  • Estimated (eGFR) > 80 mL/min/1.732 calculated with the Chronic Kidney Disease Epidemiology Collaboration formula

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness
  • Current or recent (within 3 months of study drug administration) disease of the gut that, in the opinion of the Investigator or Medical Monitor, could impact upon the absorption of study drug
  • Acute diarrhea, or constipation within 3 weeks prior to randomization
  • Any major surgery within 4 weeks of randomization

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Formulation A

    Dosage formulation and area of release varies between arms

    Drug: BMS-986165

  • Experimental
    Formulation B

    Dosage formulation and area of release varies between arms

    Drug: BMS-986165

  • Experimental
    Formulation C

    Dosage formulation and area of release varies between arms

    Drug: BMS-986165

  • Experimental
    Formulation D

    Dosage formulation and area of release varies between arms

    Drug: BMS-986165

  • Experimental
    Formulation E

    Dosage formulation and area of release varies between arms

    Drug: BMS-986165

  • Experimental
    Formulation F

    Dosage formulation and area of release varies between arms

    Drug: BMS-986165

  • Experimental
    Formulation G

    Dosage formulation and area of release varies between arms

    Drug: BMS-986165

  • Experimental
    Formulation H

    Dosage formulation and area of release varies between arms

    Drug: BMS-986165

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of BMS-986165 following Treatments A, B, C, and D

    Time frame: Determined over 5 days

  2. Time of maximum observed plasma concentration (Tmax) of BMS-986165 following Treatments A, B, C, and D

    Time frame: Determined over 5 days

  3. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of BMS-986165 following Treatments A, B, C, and D

    Time frame: Determined over 5 days

  4. Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986165 following Treatments A, B, C, and D

    Time frame: Determined over 5 days

  5. Apparent plasma elimination half-life (T-HALF) of BMS-986165 following Treatments A, B, C, and D

    Time frame: Determined over 5 days

Secondary outcomes

  1. Vital signs of body temperature

    Time frame: Up to 60 days

  2. Pulse rate

    Time frame: Up to 60 days

  3. Physical examination

    Time frame: Up to 60 days

  4. Incidence of adverse events (AE)

    Time frame: Up to 90 days

  5. Incidence of serious adverse events (SAE)

    Time frame: Up to 90 days

  6. Vital sign of respiratory rate

    Time frame: Up to 60 days

  7. Vital sign of supine blood pressure

    Time frame: Up to 60 days

07

Study locations

1 site
  • Scintipharma
    Lexington, Kentucky 40504, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in May 2019, 3 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 3 months is below that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2019
First posted
Mar 13, 2019
StartActual
Jan 25, 2019
Primary completionActual
May 1, 2019
CompletionActual
May 1, 2019
Last update
Nov 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03873415
Responsible party
Sponsor
First posted
Mar 13, 2019
Start date
Jan 25, 2019
Primary completion
May 1, 2019
Completion
May 1, 2019
Last update
Nov 26, 2019

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion